Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Thiazides and thiazide-like diuretics are one of the five major classes of antihypertensive drugs. This study is to investigate whether urinary PGE2 concentration at baseline (prior to thiazide initiation) is associated with the development of TIH within the first four weeks of treatment.
Thiazides and thiazide-like diuretics are one of the five major classes of antihypertensive drugs. They act by inhibiting the apical Na+-Cl- -cotransporter in the distal convoluted tubules of the kidneys. Thiazides and thiazide-like diuretics often cause adverse effects, importantly a drop in plasma sodium levels that is called thiazide-induced hyponatremia (TIH). Data suggest a crucial role of urinary PGE2 in water reabsorption. Since urinary PGE2 concentrations were higher in patients with TIH, quantification of urinary PGE2 prior and after thiazide initiation might allow identification of patients at risk for TIH, presenting PGE2 as a potential novel predictive marker for the development of TIH.
This study is to investigate whether urinary PGE2 concentration at baseline (prior to thiazide initiation) is associated with the development of TIH within the first four weeks of treatment. Hospitalized and ambulatory patients in whom a thiazide or thiazide-like diuretic will be newly prescribed are screened for inclusion.
The study procedure contains the screening and inclusion, visit 1 before thiazide initiation, visit 2 4 weeks (+/-7days) after thiazide initiation and a 3-months follow-up (visit 3). An additional visit (visit 2.1) will only be added in case of a dose change of the thiazide or thiazide-like diuretic (4 weeks +/- 7 days after the dose change). The 2 hours- challenge is optional if the patient agrees to additional testing.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Patients with newly prescribed thiazide or thiazide-like diuretic | As the study population of this observational study shall be as representative as possible all patients with a new thiazide or thiazide-like diuretic regardless of the indication, co-morbidities and co-medication can be included. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Data and biosample collection | Other | Collection of spot urine, blood sampling, vital parameters, body weight, medical history, patient questionnaires, drinking protocol, drug diary at at Visit 1 (before thiazide initiation), at Optional 2 hours-challenge, at Visit 2 (4 weeks after thiazide initiation), at Visit 2.1 (4 weeks after dose change), at Visit 3 (3-months after thiazide initiation) |
| Measure | Description | Time Frame |
|---|---|---|
| Occurrence of hyponatremia (plasma sodium <135 mmol/L) | Occurrence of hyponatremia (plasma sodium <135 mmol/L) | Within the first four weeks of treatment (at visit 2) |
| Measure | Description | Time Frame |
|---|---|---|
| Change in urinary Prostaglandin- concentration | Change in urinary Prostaglandin E2 (PGE2) and metabolite (PGE2M)- concentration | Between baseline, visit 2 (and visit 2.1 if applicable) and visit 3, approximately 3 months |
| Change in the expression of proteins involved in sodium and water transport |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Hospitalized and ambulatory patients in whom a thiazide or thiazide-like diuretic will be newly prescribed. Screening will take place at the University Hospital Basel and Kantonsspital Baselland, primarily at the Endocrine Outpatient Clinic and the Hypertension Clinic of the Medical Outpatient Clinic or Nephrology Department and is based on the patients' charts as well as consultation with the treating physician.
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Julia Beck, Dr. med. | Contact | +41 61 328 54 37 | julia.beck@usb.ch | |
| Joyce Santos de Jesus | Contact | joyce.santosdejesus@usb.ch |
| Name | Affiliation | Role |
|---|---|---|
| Mirjam Christ-Crain, Prof. Dr. med. | University Hospital Basel, Endocrinology, Diabetes and Metabolism | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Hospital Universitario de Móstoles | Recruiting | Móstoles | 28935 | Spain |
Not provided
| ID | Term |
|---|---|
| D007010 | Hyponatremia |
| ID | Term |
|---|---|
| D014883 | Water-Electrolyte Imbalance |
| D008659 | Metabolic Diseases |
| D009750 | Nutritional and Metabolic Diseases |
Not provided
Not provided
Not provided
Not provided
Not provided
Blood samples and Urine aliquots are stored for eventual future research aims.
|
Change in the expression of proteins involved in sodium and water transport (AQP2, Prostaglandin transporter (PGT) and NCC) in urinary extracellular vesicles in spot urine (second morning urine) |
| Between baseline, visit 2 (and visit 2.1 if applicable) and visit 3, approximately 3 months |
| Change in systolic and diastolic blood pressure | Change in systolic and diastolic blood pressure | Between baseline, visit 2 (visit 2.1 if applicable) and visit 3, approximately 3 months |
| Change in heart rate | Change in heart rate | Between baseline, visit 2 (visit 2.1 if applicable) and visit 3, approximately 3 months |
| Change in body weight | Change in body weight | Between baseline, visit 2 (visit 2.1 if applicable) and visit 3, approximately 3 months |
| Change in daily fluid intake | Change in daily fluid intake | Between baseline, visit 2 (visit 2.1 if applicable) and visit 3, approximately 3 months |
| Change in Bioelectrical impedance analysis (BIA) | Change in Bioelectrical impedance analysis (BIA) | Between baseline, visit 2 (visit 2.1 if applicable) and visit 3, approximately 3 months |
| Change in plasma sodium | Change in plasma sodium | Between baseline and visit 2 (and visit 2.1 if applicable), approximately 4 weeks |
| Change in urine sodium | Change in urine sodium | Between baseline and visit 2 (and visit 2.1 if applicable), approximately 4 weeks |
| Change in potassium | Change in potassium | Between baseline and visit 2 (and visit 2.1 if applicable), approximately 4 weeks |
| Change in chloride | Change in chloride | Between baseline and visit 2 (and visit 2.1 if applicable), approximately 4 weeks |
| Change in creatinine | Change in creatinine | Between baseline and visit 2 (and visit 2.1 if applicable), approximately 4 weeks |
| Change in urea | Change in urea | Between baseline and visit 2 (and visit 2.1 if applicable), approximately 4 weeks |
| Change in uric acid | Change in uric acid | Between baseline and visit 2 (and visit 2.1 if applicable), approximately 4 weeks |
| Change in general well-being | Change in general well-being rated on a visual analogue scale reaching from 0 to 10 | Between baseline, visit 2 (visit 2.1 if applicable) and visit 3, approximately 3 months |
| Incidence of hyponatremia | Incidence of hyponatremia | Between baseline and visit 3, approximately 3 months |
| Incidence of falls | Incidence of falls | Between baseline and visit 3, approximately 3 months |
| Incidence of fractures | Incidence of fractures | Between baseline and visit 3, approximately 3 months |
| Incidence of hospitalization due to any cause | Incidence of hospitalization due to any cause | Between baseline and visit 3, approximately 3 months |
| University Hospital Basel, Endocrinology, Diabetes and Metabolism | Recruiting | Basel | 4031 | Switzerland |
|
| Kantonsspital Baselland | Recruiting | Liestal | 4410 | Switzerland |
|